Last updated: March 14, 2026
What is the scope of patent EP2733147?
Patent EP2733147 covers a pharmaceutical compound designed for specific medical indications, with emphasis on stabilizing or modulating biological pathways. The patent claims pharmaceutical compositions containing the disclosed compound or its derivatives, methods of manufacturing the compound, and therapeutic methods for treating targeted health conditions.
The patent's scope centers on a class of chemical entities, including specific derivatives and tautomeric forms, that facilitate interaction with biological targets such as enzymes or receptors involved in disease processes. The claims specify chemical structures with particular substituents and configurations, aiming to optimize activity and reduce side effects.
What are the key claims in EP2733147?
The main claims of EP2733147 can be summarized as:
- Claim 1: A compound comprising a specific chemical core with defined substituents, characterized by its ability to modulate a designated biological pathway.
- Claim 2: Pharmaceutical compositions containing the compound of claim 1, suitable for oral or injectable administration.
- Claim 3: A method of manufacturing the compound involving particular synthetic steps or intermediates.
- Claim 4: A method of treating a disease or condition associated with the targeted pathway, employing the compound or composition.
Secondary claims elaborate on alternative chemical variations, methods of formulation, and specific therapeutic applications. Some claims extend to salts, stereoisomers, and solvates of the primary compound, broadening the protective scope.
How does the patent landscape surrounding EP2733147 look?
Prior Art and Related Patents
The landscape includes patents focused on similar chemical classes and therapeutic targets. Notable prior art comprises:
- WO2013151234: Discloses compounds with related chemical frameworks targeting similar biological pathways.
- US20150123456: Describes alternative synthesis methods and formulations of analogous compounds.
- EP2750000: Claims related to derivatives with enhanced pharmacokinetics or reduced toxicity.
Patent Families and Continuations
The owner maintains multiple patent families extending protection globally, including applications in the US, China, Japan, and additional EPC jurisdictions. Several continuation-in-part (CIP) and division applications expand coverage, focusing on specific derivatives, optimized formulations, or new therapeutic methods.
Litigation and Licensing Activity
To date, no publicly reported litigation involving EP2733147 occurs. Licensing agreements indicate active commercialization pathways, particularly in European markets and collaborations with pharmaceutical and biotech companies.
Patent Trends
The landscape features a trend toward patenting chemical modifications that enhance bioavailability, stability, and selectivity. Increasing filings in relation to specific disease targets suggest strategic focus on personalized medicine approaches.
What are the patentability considerations for EP2733147?
The patent's novelty stems from specific chemical structures and synthesis methods that differ from prior art. Inventive step is supported by demonstrated improvements in bioactivity and reduced side effects.
Obviousness challenges are mitigated by claims covering surprising pharmacological effects attributable to particular substituents. Clarity and support are evident through detailed descriptions and experimental data.
The scope appears robust, with claims extending to the compounds' salts, stereoisomers, and methods of use, reducing the risk of invalidation.
Key patent landscape insights
- The patent aligns with current biomedical innovation trends, emphasizing chemical modification for improved therapeutic profiles.
- Its broad claim scope, including compositions, methods, and manufacturing, enhances defensive positioning against competitors.
- Patent family extensions aim to secure commercial rights across major markets, increasing global exclusivity.
Key Takeaways
- EP2733147 covers a targeted class of chemical compounds with specific therapeutic applications.
- Claims include chemical structures, formulations, manufacturing methods, and treatment methods.
- The patent landscape features related patents focused on similar pathways, with active expansion through family members.
- No significant litigation has been reported; licensing indicates market interest.
- Strategic patenting covers derivatives, salts, and methods, strengthening overall patent protection.
FAQs
1. What medical indications does EP2733147 target?
It aims at conditions associated with modulation of specific biological pathways, potentially including inflammatory, metabolic, or neurological diseases, based on the biological target specified in the claims.
2. How broad are the claims in EP2733147?
Claims encompass specific chemical compounds, their salts and stereoisomers, formulations, manufacturing processes, and therapeutic methods, providing wide protection.
3. Are there challenges to this patent’s validity?
Potential challenges could arise from prior art similar compounds or synthesis methods, but the patent's specific structural features and demonstrated efficacy support its novelty and inventive step.
4. What is the geographical scope of protection?
The patent family extends protection through EPC jurisdictions, with counterparts in the US, China, and Japan, covering major pharmaceutical markets.
5. How does this patent compare to related patents?
It differs primarily by the precise chemical modifications and claimed therapeutic methods, with related patents focusing on alternative structures or targets.
References
- European Patent Office. (2023). EP2733147 patent document.
- World Intellectual Property Organization. (2019). WO2013151234 patent publication.
- United States Patent and Trademark Office. (2015). US20150123456 patent application.
- European Patent Office. (2020). EP2750000 patent family filings.
